223 related articles for article (PubMed ID: 16091248)
1. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.
Lee GA; Rao MN; Grunfeld C
Curr HIV/AIDS Rep; 2005 Feb; 2(1):39-50. PubMed ID: 16091248
[TBL] [Abstract][Full Text] [Related]
2. The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.
Lee GA; Rao MN; Grunfeld C
Curr Infect Dis Rep; 2004 Dec; 6(6):471-482. PubMed ID: 15538985
[TBL] [Abstract][Full Text] [Related]
3. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.
Behrens G; Dejam A; Schmidt H; Balks HJ; Brabant G; Körner T; Stoll M; Schmidt RE
AIDS; 1999 Jul; 13(10):F63-70. PubMed ID: 10416516
[TBL] [Abstract][Full Text] [Related]
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
5. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
6. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
Moyle GJ
AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769
[No Abstract] [Full Text] [Related]
8. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
9. Management of protease inhibitor-associated hyperlipidemia.
Penzak SR; Chuck SK
Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
[TBL] [Abstract][Full Text] [Related]
10. HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Lenhard JM; Croom DK; Weiel JE; Winegar DA
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2625-9. PubMed ID: 11116063
[TBL] [Abstract][Full Text] [Related]
11. Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
Dubé MP
Clin Infect Dis; 2000 Dec; 31(6):1467-75. PubMed ID: 11096014
[TBL] [Abstract][Full Text] [Related]
12. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
13. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.
Melvin AJ; Lennon S; Mohan KM; Purnell JQ
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1117-23. PubMed ID: 11522181
[TBL] [Abstract][Full Text] [Related]
14. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
15. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
[TBL] [Abstract][Full Text] [Related]
16. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
17. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
[TBL] [Abstract][Full Text] [Related]
18. [Blood lipid abnormalities during treatment with protease inhibitors].
Vergès B; Petit JM
Presse Med; 2001 May; 30(18):911-4. PubMed ID: 11413853
[TBL] [Abstract][Full Text] [Related]
19. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus.
Ergun-Longmire B; Lin-Su K; Dunn AM; Chan L; Ham K; Sison C; Stavola J; Vogiatzi MG
Endocr Pract; 2006; 12(5):514-21. PubMed ID: 17014060
[TBL] [Abstract][Full Text] [Related]
20. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
